PDCD1 and metastatic colorectal cancer: To date, immunotherapeutics, against the programmed cell death protein-1 (PD-1)/programmed cell death protein-1 ligand (PD-L1) axis, have been approved by the Food and Drug Administration for metastatic colorectal cancer (mCRC) with microsatellite instability (MSI)-high (H) only (7).